Active, not recruitingPhase 2NCT05733572
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)
Studying Optic pathway glioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Benedetto Falsini
- Principal Investigator
- Benedetto Falsini, MDuniversita Cattolica del S. Cuore/Fondazione policlinico A. Gemelli, IRCCS
- Intervention
- CHF6467(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 3-40 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- Catholic University, Policlinico A. Gemelli (Hospital), Rome, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05733572 on ClinicalTrials.govOther trials for Optic pathway glioma
Additional recruiting or active studies for the same condition.